Clarient, Inc announced the commercial launch of its new gene expression test for prostate cancer. This new test will be available through Clarient's PATHSiTE virtual reporting tool and accessible to the company's entire pathology network Clarient's new test is based on combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells in prostate tissue. The association of the four genes with prostate cancer was discovered by Health Discovery Corporation using their patented SVM and SVM-RFE pattern recognition technology. Working with Health Discovery Corporation, we have now completed the scientific paper documenting our validation results and have submitted our work to a respected international medical journal for peer review and publication which will be paramount to our marketing efforts" said Ron Andrews, Clarient's Chief Executive Officer. The two companies also announced that in order to insure market uptake of the new prostate cancer test, they will transition to a non-exclusive agreement so as to allow for licensing to additional laboratories. Under the amended agreement, Clarient will retain the exclusive rights for a prognostic test which may be developed in the future in conjunction with Health Discovery Corporation. Dr. Barnhill continued, "The high sensitivity and specificity demonstrated in the validation results of our new prostate cancer test suggest that this new molecular diagnostic could assist physicians in more accurately identifying the presence of prostate cancer in patients with both positive and negative biopsies."